Blue Earth Therapeutics Announces U.S. FDA Clearance for Investigational New Drug (IND) Application for 177Lu-rhPSMA-10.1

177Lutetium-labelled radiohybrid Prostate-Specific Membrane Antigen (177Lu-rhPSMA-10.1) is a highly optimized, next generation therapeutic radiopharmaceutical 

Related Keywords

Germany ,United States ,Munich ,Bayern ,Scintomics Gmb ,Davide Gauden , ,Technical University Of Munich ,Company Investigational New Drug Application ,Drug Administration ,Blue Earth Therapeutics ,Investigational New Drug Application ,Blue Earth Therapeutic ,Earth Therapeutics ,Prostate Specific Membrane Antigen ,Chief Executive Officer ,Radiohybrid Prostate Specific Membrane Antigen ,Prostate Specific Membrane Antigen Targeted ,Technical University ,Blue Earth Diagnostics ,Scintomics Gmbh ,Blue Earth ,